{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:35:42Z","timestamp":1783654542142,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.therap.2024.10.056","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:24:50Z","timestamp":1729643090000},"page":"213-222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["From regional signal to alert in addictovigilance"],"prefix":"10.1016","volume":"80","author":[{"given":"Am\u00e9lie","family":"Daveluy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Perino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Gibaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reynald","family":"Le Boisselier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Batisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada","family":"Miremont-Salam\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Peyr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Frauger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Peyri\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2024.10.056_bib0250","series-title":"Strat\u00e9gie nationale de sant\u00e9 2023\u20132033","year":"2023"},{"key":"10.1016\/j.therap.2024.10.056_bib0255","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2515\/therapie\/2015009","article-title":"Signal identification in addictovigilance: the functioning of the French system","volume":"70","author":"Jouanjus","year":"2015","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.056_bib0260","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.therap.2019.09.005","article-title":"Safety signal detection by the French Addictovigilance Network: innovative methods of investigation, examples and usefulness for public health","volume":"74","author":"Micallef","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.056_bib0265","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.therap.2016.05.001","article-title":"Twenty-five years of the French Addictovigilance Network (FAN)","volume":"71","author":"Micallef","year":"2016","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.056_bib0270","doi-asserted-by":"crossref","first-page":"e060519","DOI":"10.1136\/bmjopen-2021-060519","article-title":"Protocol for a scoping review on misuse of psychoactive medicines and its consequences","volume":"12","author":"Araujo","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.therap.2024.10.056_bib0275","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1111\/bcp.13272","article-title":"Early signal of diverted use of tropicamide eye drops in France","volume":"83","author":"Ponte","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.056_bib0280","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s40263-024-01095-y","article-title":"Patterns of pregabalin users from substance abuse treatment facilities: results from the French OPPIDUM program from 2008 to 2022","volume":"38","author":"Garnier","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.therap.2024.10.056_bib0285","series-title":"European Drug Report 2024: trends and developments","year":"2024"},{"key":"10.1016\/j.therap.2024.10.056_bib0290","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.therap.2024.05.004","article-title":"Isotonitazene, a synthetic opioid from an emerging family: the nitazenes","volume":"79","author":"Bendjilali-Sabiani","year":"2024","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.056_bib0295","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.addbeh.2017.11.021","article-title":"Parachuting psychoactive substances: pharmacokinetic clues for harm reduction","volume":"78","author":"Daveluy","year":"2018","journal-title":"Addict Behav"},{"key":"10.1016\/j.therap.2024.10.056_bib0300","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/fcp.12172","article-title":"Illicit drugs or medicines taken by parachuting","volume":"30","author":"Daveluy","year":"2016","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.056_bib0305","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.therap.2023.10.017","article-title":"Psychoactive substance intoxication leading to general hospital admission in young and middle-aged people during and after the first lockdown","volume":"79","author":"Perino","year":"2024","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.056_bib0310","first-page":"14","article-title":"Substance use disorders among French older adults: main trends from the perspective of addictovigilance data","volume":"33","author":"Daveluy","year":"2019","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.056_bib0315","article-title":"Sex\/gender differences in spontaneous reports to a French Addictovigilance centre","author":"Peyriere","year":"2024","journal-title":"Arch Womens Ment Health"},{"key":"10.1016\/j.therap.2024.10.056_bib0320","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/fcp.12725","article-title":"Chemsex practice in France: an update in Addictovigilance data","volume":"36","author":"Batisse","year":"2022","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.056_bib0325","doi-asserted-by":"crossref","first-page":"102297","DOI":"10.1016\/j.legalmed.2023.102297","article-title":"Assessment of 19 years of a prospective national survey on drug-facilitated crimes in France","volume":"65","author":"Djezzar","year":"2023","journal-title":"Leg Med (Tokyo)"},{"key":"10.1016\/j.therap.2024.10.056_bib0330","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/fcp.12815","article-title":"Ten-year trends in hospitalizations related to cocaine abuse in France","volume":"36","author":"Eiden","year":"2022","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.056_bib0335","doi-asserted-by":"crossref","DOI":"10.1111\/fcp.12995","article-title":"Patterns of ketamine use among people with substance use disorder in France: multisource analysis of the data from the French Addictovigilance Network","author":"Gandolfo","year":"2024","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.056_bib0340","doi-asserted-by":"crossref","first-page":"104082","DOI":"10.1016\/j.drugpo.2023.104082","article-title":"General hospital admissions in young and middle-aged people who use psychoactive substances: impact of Covid-19 lockdowns","volume":"118","author":"Perino","year":"2023","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.therap.2024.10.056_bib0345","doi-asserted-by":"crossref","first-page":"e2331398","DOI":"10.1001\/jamanetworkopen.2023.31398","article-title":"Trends in fatal poisoning among drug users in France from 2011 to 2021: an analysis of the DRAMES Register","volume":"6","author":"Revol","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.therap.2024.10.056_bib0350","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/add.16081","article-title":"The opioid epidemic: a worldwide exploratory study using the WHO pharmacovigilance database","volume":"118","author":"Robert","year":"2023","journal-title":"Addiction"},{"key":"10.1016\/j.therap.2024.10.056_bib0355","doi-asserted-by":"crossref","first-page":"109096","DOI":"10.1016\/j.thromres.2024.109096","article-title":"Thromboembolic complications following recreational use of nitrous oxide: a French Addictovigilance alert","volume":"241","author":"Victorri-Vigneau","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.therap.2024.10.056_bib0360","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.therap.2018.07.007","article-title":"From psychoactive medicines to addictovigilance in French Public Health Code (1990\u20132017)","volume":"74","author":"Baumevieille","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.056_bib0365","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.therap.2017.01.010","article-title":"Surveillance system on drug abuse: interest of the French national OPPIDUM program of French addictovigilance network","volume":"72","author":"Frauger","year":"2017","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.056_bib0370","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/fcp.12356","article-title":"Medical prescriptions falsified by the patients: a 12-year national monitoring to assess prescription drug diversion","volume":"32","author":"Jouanjus","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.056_bib0375","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40264-021-01124-5","article-title":"A 13-year national monitoring study to assess narcotic prescriptions and indications (2007\u20132019)","volume":"45","author":"Perri-Plande","year":"2022","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2024.10.056_bib0380","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1111\/bcp.15323","article-title":"Increase of high-risk tramadol use and harmful consequences in France from 2013 to 2018: evidence from the triangulation of addictovigilance data","volume":"88","author":"Roussin","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.056_bib0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.puhe.2023.07.004","article-title":"Increase in hospitalisation-associated methadone intoxication in France following first COVID-19 lockdown","volume":"223","author":"Perino","year":"2023","journal-title":"Public Health"},{"key":"10.1016\/j.therap.2024.10.056_bib0390","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/pds.3369","article-title":"Identification of abuse and dependence cases through a hospital database","volume":"21","author":"Daveluy","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2024.10.056_bib0395","first-page":"202","article-title":"Inputs of pharmacoedemiology in addictovigilance","volume":"80","author":"Soiero","year":"2025","journal-title":"Therapies"},{"key":"10.1016\/j.therap.2024.10.056_bib0400","first-page":"61","article-title":"Importance of the consumption of a new drug called chimique in the French departments of Indian Ocean (Mayotte and Reunion Island)","volume":"35","author":"Goncalves","year":"2021","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.056_bib0405","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.therap.2021.01.024","article-title":"Consommation de substances psychoactives illicites par vapotage\u00a0: les donn\u00e9es d\u2019addictovigilance","volume":"76","author":"Batisse","year":"2021","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.056_bib0410","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1080\/15563650.2021.1994144","article-title":"Involuntary MDMB-4en-PINACA intoxications following cannabis consumption: clinical and analytical findings","volume":"60","author":"Goncalves","year":"2022","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.therap.2024.10.056_bib0415","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/ADM.0000000000000324","article-title":"Misuse of novel synthetic opioids: a deadly new trend","volume":"11","author":"Prekupec","year":"2017","journal-title":"J Addict Med"},{"key":"10.1016\/j.therap.2024.10.056_bib0420","series-title":"Report on the risk assessment of N,N-diethyl-2-[[4-(1-ethylethoxy)phenyl]methyl]-5-nitro-1Hbenzimidazole-1-ethanamine (isotonitazene) in accordance with Article 5c of Regulation (EC) No 1920\/2006 (as amended)","year":"2020"},{"key":"10.1016\/j.therap.2024.10.056_bib0425","series-title":"Potent synthetic opioids implicated in heroin overdoses and deaths","year":"2023"},{"key":"10.1016\/j.therap.2024.10.056_bib0430","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.therap.2022.10.052","article-title":"Nouvelle classe \u00e9mergente \u00e0 risques\u00a0: les \u00ab\u00a0nitazenes\u00a0\u00bb\u00a0: \u00e0 propos du 1er cas national d\u2019addictovigilance","volume":"77","author":"Savignat","year":"2022","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.056_bib0435","series-title":"Le point SINTES","year":"2022"},{"key":"10.1016\/j.therap.2024.10.056_bib0440","first-page":"10","article-title":"Involuntary nitazene intoxications following \u201cchimique\u201d consumption: clinical and analytical findings","volume":"38","author":"Daveluy","year":"2024","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.056_bib0445","series-title":"Circulation des nitazenes, nouveaux opio\u00efdes de synth\u00e8se et risques pour les usagers","year":"2023"},{"key":"10.1016\/j.therap.2024.10.056_bib0450","series-title":"Les autorit\u00e9s de sant\u00e9 alertent sur la circulation croissante d\u2019opio\u00efdes de synth\u00e8se, dont une nouvelle classe particuli\u00e8rement dangereuse, d\u00e9sormais inscrite sur la liste des stup\u00e9fiants","year":"2024"},{"key":"10.1016\/j.therap.2024.10.056_bib0455","doi-asserted-by":"crossref","first-page":"639780","DOI":"10.3389\/fpsyt.2021.639780","article-title":"Gabapentinoid abuse in France: evidence on health consequences and new points of vigilance","volume":"12","author":"Tambon","year":"2021","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.therap.2024.10.056_bib0460","series-title":"Bulletin \u00ab\u00a0Une crise des gabapentino\u00efdes?\u00a0\u00bb","year":"2019"},{"key":"10.1016\/j.therap.2024.10.056_bib0465","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2515\/therapie\/2015012","article-title":"Example of an investigation of an \u201cemergent\u201d phenomenon in addiction vigilance: the case of methylphenidate","volume":"70","author":"Micallef","year":"2015","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.056_bib0470","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.therap.2022.10.027","article-title":"Analyse d\u2019un signal d\u2019augmentation du d\u00e9tournement du m\u00e9thylph\u00e9nidate en Aquitaine","volume":"77","author":"Miremont","year":"2022","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.056_bib0475","series-title":"Message d\u2019information sur les \u00e9v\u00e9nements sanitaires","year":"2023"},{"key":"10.1016\/j.therap.2024.10.056_bib0480","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.therap.2022.03.006","article-title":"Increasing methylphenidate abuse: tracking and profiles during 13-years","volume":"77","author":"Guerra","year":"2022","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.056_bib0485","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.therap.2020.01.001","article-title":"Augmentation des complications sanitaires graves lors de l\u2019usage non-m\u00e9dical du protoxyde d\u2019azote en France","volume":"76","author":"Micallef","year":"2021","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.056_bib0490","series-title":"Information du r\u00e9seau fran\u00e7ais d\u2019addictovigilance. Int\u00e9r\u00eat d\u2019une diffusion large de naloxone","year":"2021"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724001720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724001720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T12:34:07Z","timestamp":1744202047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595724001720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0040595724001720"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2024.10.056","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From regional signal to alert in addictovigilance","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2024.10.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}